. . . "3" . . "Ml\u010D\u016Fchov\u00E1, Dana" . "RIV/61989592:15110/14:33144644" . "5"^^ . "therapeutic outcome; relative dose intensity; chemotherapy; primary treatment; Hodgkin lymphoma"@en . "Proch\u00E1zka, V\u00EDt" . . "Reduced relative dose intensity of primary chemotherapy does not influence prognosis of patients with Hodgkin lymphoma" . . "15110" . . . "8"^^ . . "Indr\u00E1k, Karel" . "RIV/61989592:15110/14:33144644!RIV15-MSM-15110___" . . . "Reduced relative dose intensity of primary chemotherapy does not influence prognosis of patients with Hodgkin lymphoma" . "Reduced relative dose intensity of primary chemotherapy does not influence prognosis of patients with Hodgkin lymphoma"@en . "158" . . . . . . "6"^^ . . "Faber, Edgar" . . "Aims: A retrospective analysis of patients with Hodgkin lymphoma (HL) was performed to assess their outcome regarding relative dose intensity (RDI) of chemotherapy administered in primary treatment. Methods: A total of 194 patients were divided into three groups with different RDI of primary chemotherapy (100%, 90-99% and { 90%). Reduced RDI in two groups (90-99% and { 90%) was caused by the delay of the interval between the administration of some chemotherapeutic courses. The probability of complete remission (CR), disease relapse, event-free survival (EFS) and overall survival (OS) as the basic parameters of patient outcome were statistically compared. Results: Multivariate analysis showed here were no significant differences in probability of CR (HR 0.9, 95% CI [0.75-1.08], P=0.5), risk of relapse (HR 1.34, 95% CI [0.92-1.94], P=0.11) or death (HR 1.52, 95% CI [0.94-2.5], P=0.13). There were also no significant differences in probability of EFS (mean 13 vs. 10 vs. 12 years, P=0.17; HR 1.54, 95% CI [0.91-2.6], P=0.22) or OS (mean 15 vs. 13 vs. 14 years, P=0.13; HR 1.52, 95% CI [0.93-2.5], P=0.13). Conclusion: We found no significant impact of primary chemotherapy delay resulting in reduced RDI on outcome in HL patients."@en . "Raida, Lud\u011Bk" . "P(EE2.3.20.0170), S, Z(MSM6198959205)" . "Reduced relative dose intensity of primary chemotherapy does not influence prognosis of patients with Hodgkin lymphoma"@en . "Rusi\u0148\u00E1kov\u00E1, Zuzana" . . "Biomedical Papers-Olomouc" . . . "1213-8118" . "Aims: A retrospective analysis of patients with Hodgkin lymphoma (HL) was performed to assess their outcome regarding relative dose intensity (RDI) of chemotherapy administered in primary treatment. Methods: A total of 194 patients were divided into three groups with different RDI of primary chemotherapy (100%, 90-99% and { 90%). Reduced RDI in two groups (90-99% and { 90%) was caused by the delay of the interval between the administration of some chemotherapeutic courses. The probability of complete remission (CR), disease relapse, event-free survival (EFS) and overall survival (OS) as the basic parameters of patient outcome were statistically compared. Results: Multivariate analysis showed here were no significant differences in probability of CR (HR 0.9, 95% CI [0.75-1.08], P=0.5), risk of relapse (HR 1.34, 95% CI [0.92-1.94], P=0.11) or death (HR 1.52, 95% CI [0.94-2.5], P=0.13). There were also no significant differences in probability of EFS (mean 13 vs. 10 vs. 12 years, P=0.17; HR 1.54, 95% CI [0.91-2.6], P=0.22) or OS (mean 15 vs. 13 vs. 14 years, P=0.13; HR 1.52, 95% CI [0.93-2.5], P=0.13). Conclusion: We found no significant impact of primary chemotherapy delay resulting in reduced RDI on outcome in HL patients." . "Tu\u010Dek, Pavel" . "CZ - \u010Cesk\u00E1 republika" . "[65B608A3F1C6]" . . . . "41701" . . "Papaj\u00EDk, Tom\u00E1\u0161" . "10.5507/bp.2013.022" .